This page shows the publications co-authored by Marilyn Moy and Eric Garshick.
Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD. Chest. 2014 Mar 01; 145(3):542-550.
An index of daily step count and systemic inflammation predicts clinical outcomes in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014 Feb; 11(2):149-57.
Daily step count predicts acute exacerbations in a US cohort with COPD. PLoS One. 2013; 8(4):e60400.
Daily step counts in a US cohort with COPD. Respir Med. 2012 Jul; 106(7):962-9.
Free-living physical activity in COPD: assessment with accelerometer and activity checklist. J Rehabil Res Dev. 2009; 46(2):277-86.
Respiratory symptoms and intensity of occupational dust exposure. Int Arch Occup Environ Health. 2004 Oct; 77(7):515-20.
Molecular markers of aging, exercise capacity, & physical activity in COPD. Respir Med. 2021 10; 187:106576.
Long-term effects of web-based pedometer-mediated intervention on COPD exacerbations. Respir Med. 2020 02; 162:105878.
Effects of Indoor and Ambient Black Carbon and [Formula: see text] on Pulmonary Function among Individuals with COPD. Environ Health Perspect. 2018 12; 126(12):127008.
Indoor black carbon and biomarkers of systemic inflammation and endothelial activation in COPD patients. Environ Res. 2018 08; 165:358-364.
Indoor black carbon of outdoor origin and oxidative stress biomarkers in patients with chronic obstructive pulmonary disease. Environ Int. 2018 06; 115:188-195.
Promoting physical activity in COPD: Insights from a randomized trial of a web-based intervention and pedometer use. Respir Med. 2017 Sep; 130:102-110.
Use of pedometer and Internet-mediated walking program in patients with chronic obstructive pulmonary disease. J Rehabil Res Dev. 2010; 47(5):485-96.
Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease. J Rehabil Res Dev. 2009; 46(5):643-54.
Accuracy of uniaxial accelerometer in chronic obstructive pulmonary disease. J Rehabil Res Dev. 2008; 45(4):611-7.
Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. Pulm Circ. 2013 Dec; 3(4):889-97.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.